Celldex Therapeutics Inc is a biotechnology business based in the US. Celldex Therapeutics shares (CLDX) are listed on the NASDAQ and all prices are listed in US Dollars. Celldex Therapeutics employs 123 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Guided investing
Our top pick for
Building a portfolio
Our top pick for
Beginners
| Latest market close | $30.32 |
|---|---|
| 52-week range | $15.37 - $57.20 |
| 50-day moving average | $39.43 |
| 200-day moving average | $39.25 |
| Wall St. target price | $65.17 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.76 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $30.32 from 2022-01-19
| 1 week (2022-01-13) | 0.66% |
|---|---|
| 1 month (2021-12-20) | -22.49% |
| 3 months (2021-10-16) | N/A |
| 6 months (2021-07-20) | -30.22% |
| 1 year (2021-01-20) | 61.97% |
|---|---|
| 2 years (2020-01-17) | 1,137.55% |
| 3 years (2019-01-18) | 8,778.48% |
| 5 years (2017-01-20) | 789.15% |
| Revenue TTM | $8.1 million |
|---|---|
| Gross profit TTM | $-35,116,000 |
| Return on assets TTM | -10.27% |
| Return on equity TTM | -21.68% |
| Profit margin | 0% |
| Book value | $9.36 |
| Market capitalisation | $1.5 billion |
TTM: trailing 12 months
We're not expecting Celldex Therapeutics to pay a dividend over the next 12 months.
Celldex Therapeutics's shares were split on a 1:15 basis on 10 February 2019. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Celldex Therapeutics shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Celldex Therapeutics shares which in turn could have impacted Celldex Therapeutics's share price.
Over the last 12 months, Celldex Therapeutics's shares have ranged in value from as little as $15.37 up to $57.2. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Celldex Therapeutics's is 2.7248. This would suggest that Celldex Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Celldex Therapeutics, Inc. , a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. Celldex Therapeutics, Inc. has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University.
Donut earns up to 10% APY, but you must have an iOS device.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.
Everything we know about the VinFast IPO, plus information on how to buy in.
Creating a golf club is a thus-far unique application of NFTs, and another step forward for the decentralized economy.
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.
Everything we know about the Specialty Building Products IPO, plus information on how to buy in.
Everything we know about the HeartCore Enterprises IPO, plus information on how to buy in.